Comparison of Anxiety Scores on the State-Trait Anxiety Inventory – State Subscale (STAI-State) by Treatment ConditionĮFigure 7. Effect Size Calculation Using Cohen’s d StatisticĮFigure 6. Comparison of Anxiety Scores on the Hamilton Anxiety Scale (HAM-A) by Treatment Condition (Immediate vs Delayed). Comparison of Depression Scores on the Patient Health Questionnaire – 9 Item (PHQ-9) by Treatment ConditionĮFigure 5. Comparison of Depression Scores on the Beck Depression Inventory – II (BDI-II) by Treatment ConditionĮFigure 4. Comparison of Depression Scores on the Quick Inventory of Depression Symptoms (QIDS-SR) by Treatment ConditionĮFigure 3. Decrease in Depression Scores on the Quick Inventory of Depression Symptoms (QIDS-SR) from Baseline to 1-day Post Psilocybin Session 1 and Through the 4-week Follow-upĮFigure 2. Initiation of Antidepressant Medication, Psychotherapy, or Psilocybin Reported 4 weeks After Session 2ĮFigure 1. Adverse Effects Reported the Day After Sessions 1 and 2 That Were Rated by Staff as Possibly or Probably Related to PsilocybinĮTable 10. Adverse Emotional and Physical Effects During Psilocybin SessionsĮTable 9. Data Regarding Number of Participants Requiring Increased Rate of MonitoringĮTable 8. Mean of the Peak Heart Rate and Blood Pressure Across Participants During Each of Two Psilocybin Sessions. Monitor Ratings of Peak Psilocybin Effects During Each of Two Psilocybin SessionsĮTable 7. Mean Proportion (and Standard Deviation) of Total Possible Score on the Mystical and Challenging Experiences Questionnaires During Each of Two Psilocybin Sessions Proportion of Participants Who Had a Complete Mystical Experience in Each SessionĮTable 6. Ratings of Personal Meaning, Spiritual Significance, Psychological Challenge, and Psychological Insight During Each of Two Psilocybin SessionsĮTable 5. Repeated Measures ANOVAs and Effect Sizes for Depression, Anxiety, and Suicidal Ideation Outcomes Across Overall SampleĮTable 4. t Tests Comparing Depression, Anxiety, and Suicidal Ideation Outcomes at Each Timepoint by ConditionĮTable 3. Repeated Measures ANOVAs Comparing Depression, Anxiety, and Suicidal Ideation Outcomes at Each Timepoint by Treatment ConditionĮTable 2. Sleep difficulties were also reported at screening, and it was not clear whether sleep difficulties were exacerbated by the intervention.ĮParticipant showed a marked reduction in depression symptoms immediately following the first psilocybin session and chose not to proceed with the intervention.ĮTable 1. Forty-five people were ineligible for other reasons.īPeople were deemed ineligible during in-person screening if they had a psychiatric condition judged to be incompatible with establishment of rapport or safe exposure to psilocybin (n = 17) did not have confirmed DSM-5 diagnosis of MDD (n = 7) had a recent history of moderate to severe substance use disorder (n = 5) were at high risk for suicidality (n = 3) disagreed with study procedures (n = 3) had a baseline GRID Hamilton Depression Rating Scale score lower than the eligibility threshold of 17 (n = 2) had cardiovascular conditions (n = 2) had lifetime hallucinogen use that exceeded the exclusion threshold (n = 2) were currently taking serotonergic medication (n = 1) or were more than 25% beyond the upper and lower range of recommended body weight (n = 1).ĬDropped out of the study due to anticipatory anxiety about the upcoming first psilocybin session.ĭDropped out of study due to sleep difficulties. AAfter completing the prescreening questionnaire, people were deemed ineligible if they were currently using antidepressant medication (n = 157) lived outside reasonable commuting distance (n = 161) did not meet criteria for the magnetic resonance imaging scans (n = 99) had a first- or second-degree relative with a diagnosis of schizophrenia spectrum, bipolar I or II, or other psychotic disorder ( = 77) had a recent history of substance use disorder (n = 50) opted out of in-person screening (n = 38) were not in a current depressive episode (n = 37) were more than 25% beyond the upper or lower range of recommended body weight (n = 32) had a medically significant suicide attempt (n = 30) had lifetime hallucinogen use that exceeded the exclusion threshold (n = 30) if major depressive disorder (MDD) was not primary psychiatric diagnosis (n = 18) if they had a medical exclusion (n = 11) had exclusionary use of nonserotonergic psychoactive medication (n = 11) or failed to respond to electroconvulsive therapy during current depressive episode (n = 4).
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |